A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies
Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, James R. Berenson, William J. Edenfield, Sanjay Mohan, Gongfu Zhou, Ekaterine Asatiani, Nithya Srinivas, Michael R. Savona
Topics & Concepts
MedicineTolerabilityInternal medicineAzacitidineOncologyPhases of clinical researchDiscontinuationRuxolitinibAdverse effectNeutropeniaClinical trialBone marrowChemotherapyMyelofibrosisBiochemistryGene expressionDNA methylationChemistryGeneMyeloproliferative Neoplasms: Diagnosis and TreatmentCytokine Signaling Pathways and InteractionsAcute Myeloid Leukemia Research